Skip to content
FrontierPicks

In the portfolio

LLY · Eli Lilly and Company

Conviction · Medium Theme leader Catalyst ·

Updated ·

Against its published line

Above its line on the last close.

How to read this

The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 30 October 2026; a dot left of the mark has closed through its line.

Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.

How a pick is graded

LLYEli Lilly and Company
$1,250.00
$1,417.54
+13.4%well clear

Kill line

A daily close below $1,250, which would erase the full 29 October 2026 post-earnings gain and sit under the $1,288.30 pre-report close. A cut to the $91.0–$92.0 billion 2026 revenue guidance would also end the case.

Open pick Medium conviction, opened at $1,149.85. Since then +17.8% against the S&P 500's −3.8% (+21.5 pp). Kill line at open: $1,050.00 (daily close); graded by at the latest.

In the portfolio Since : +12.9%. See the portfolio.

Catalyst (in 23 days)

How picks are graded →

The thesis

Eli Lilly's tirzepatide volume is still growing faster than its prices are falling, and the raised 2026 revenue guidance of $91.0–$92.0 billion supports that reading. The fourth-quarter report and first 2027 outlook, expected around 4 February 2027, settle whether it lasts after Novo Nordisk's US list-price cuts take effect on 1 January 2027.

Novo's 4 November 2026 report is the main new fact since the previous note. It leaves the case intact and makes the competition harder. Novo raised its 2026 outlook and said its Wegovy franchise has more than 50% of new patient starts in the US branded obesity market (Form 6-K). Novo's management also said the US obesity category was relatively flat from May to October once Medicare Bridge prescriptions are excluded (Zacks call summary, 5 November 2026).

The narrative is maturing: Lilly's market value passed Berkshire Hathaway's on 20 October 2026 (Yahoo Finance), at least seven brokers lifted targets on 30 October 2026, and Cantor Fitzgerald, Berenberg and BofA Securities followed by 5 November 2026. That agreement leaves less room for a positive surprise before the February report.

Bullish and bearish views on Eli Lilly and Company

The bull case on Eli Lilly and Company (LLY), in brief: Volume is still outrunning price. The bear case: Price erosion is deepening.

Bull case

  • Volume is still outrunning price. Third-quarter revenue rose 39% to $24.4 billion on 53% higher volume and 15% lower realized prices, according to Lilly's 29 October 2026 Form 8-K. US volume rose 41% against a 7% US price decline.
  • Both tirzepatide brands grew quickly. Mounjaro sales rose 65% to $10.7 billion and Zepbound rose 49% to $5.35 billion (Form 8-K, 29 October 2026). GuruFocus put consensus near $10.04 billion and $5.03 billion on 28 October 2026.
  • Guidance rose for the third time this year. Lilly lifted 2026 revenue guidance to $91.0–$92.0 billion from $85.0–$87.0 billion and its performance-margin guidance to 52.0–52.5% from 49.0–50.5% (Form 8-K, 29 October 2026).
  • Retatrutide beat Ozempic head to head. In the 80-week TRANSCEND-T2D-2 trial, weight fell 19.5% (9 mg) and 20.9% (12 mg) against 9.4% for semaglutide 2 mg (HCPLive, 28 October 2026). Lilly plans a US filing in the first quarter of 2027.
  • Self-pay distribution keeps widening. LifeMD said on 5 November 2026 that its pharmacies will directly dispense and ship Lilly's self-pay GLP-1 medicines, including Zepbound and Foundayo (Benzinga, fiscal.ai).
  • Analyst targets kept rising after the report. Cantor Fitzgerald raised its target to $1,600 from $1,440 and Berenberg to $1,570 from $1,400 on 2 November 2026, and BofA Securities raised its target to $1,557 from $1,497 on 5 November 2026 (fiscal.ai). JPMorgan's $1,650 target from 30 October 2026 remains among the highest reported (Benzinga).

Bear case

  • Price erosion is deepening. US realized prices fell 7% and prices outside the US fell 29% in the third quarter (Form 8-K, 29 October 2026). The US decline was 3% in the second quarter.
  • Zacks reported on 5 November 2026 that it has about 80% of new-to-brand oral obesity prescriptions, while Foundayo sold $184 million against a $229 million FactSet consensus (CNBC, 29 October 2026).
  • Category growth leans on Medicare. Novo's management said sequential growth was "substantially supported by Bridge prescriptions," the Medicare coverage that began on 1 July 2026 (Zacks, 5 November 2026; Form 6-K). If that also describes Lilly's US volume, growth depends more on a low-priced channel; Zepbound growth slowing sharply in the fourth-quarter report would confirm it.
  • Part of the beat was one-time. 24/7 Wall St. reported on 29 October 2026 that about $900 million of third-quarter revenue came from one-time items, including $410 million in Jardiance milestones.
  • Earnings guidance fell while revenue guidance rose. Adjusted (non-GAAP) earnings guidance dropped to $35.00–$36.00 per share from $35.50–$36.50 after $4.57 per share of acquired in-process research charges (Form 8-K, 29 October 2026).
  • A large shareholder filed to sell again. Lilly Endowment gave notice on 1 November 2026 of a proposed sale of 295,000 shares valued at about $405.24 million (fiscal.ai). Ark Invest reported selling $25 million of Lilly shares on 2 November 2026 (fiscal.ai).

Price setup

The shares closed at $1,364.73 on 5 November 2026, 3.8% below the 52-week high of $1,417.99, on adjusted daily closes. That close is under the $1,373.70 close on report day, 29 October 2026, and above the $1,288.30 close before the report. The shares rose 10.9% over three months.

The 14-day relative strength index (RSI), a momentum gauge, fell to 65.1 on 5 November 2026 from 79.9 on 30 October 2026, so the overbought reading after the report has cooled. The observable crowding evidence is the Lilly Endowment sale notice, the Ark Invest sale and the cluster of broker target increases. No Lilly earnings report falls in the next 30 days. A close back under $1,288.30 would erase the whole report-day gain.

Catalysts, next 30 days

  • ~30 November 2026, est.: The US government's expected publication of negotiated Medicare prices for the third negotiation cycle, which includes Lilly's Trulicity and Verzenio. The prices take effect in 2028, so this tests the older portfolio more than tirzepatide.
  • ~15 December 2026, est.: European Commission decision on Foundayo (orforglipron), after the 15 October 2026 positive opinion from the European Medicines Agency's drug committee.
  • ~31 December 2026, est.: Phase 3 start for eloraTZP, which Lilly guided for the fourth quarter of 2026.
  • 1 January 2027: Novo's US list-price cuts for Wegovy, Ozempic and Rybelsus to $675 a month take effect.
  • ~4 February 2027, est.: Fourth-quarter 2026 results and first 2027 guidance. This report decides the case.
  • ~31 March 2027, est.: Planned US filing for retatrutide, guided for the first quarter of 2027.

What would change the view

The case breaks if price erosion overtakes volume. Three results would show that: a cut to the $91.0–$92.0 billion 2026 revenue guidance, fourth-quarter US realized prices falling well beyond the 7% third-quarter decline with slower Mounjaro and Zepbound growth, or a 2027 outlook that points to sharply slower tirzepatide revenue growth.

Major US payer formularies favouring Wegovy over Zepbound for 2027, or Lilly citing US share loss on its fourth-quarter call, would also weaken it. On price, a daily close below $1,250 ends the thesis. That level would erase the full 29 October 2026 post-earnings gain and sit under the $1,288.30 pre-report close.

What it trades with

Novo Nordisk is the closest read-across because it sells into the same US obesity market and the same Medicare Bridge coverage. Its news can cut both ways for Lilly: wider Medicare access helps both companies, while Wegovy pill share comes directly at Foundayo's expense.

Drug-pricing policy is the shared risk with large US pharmaceutical companies. PhRMA, the industry trade group, sued over a Medicare rule on 8 October 2026, and the third Medicare negotiation cycle covers drugs from many manufacturers. Lilly's own results still rest mainly on tirzepatide, with Mounjaro and Zepbound together reaching $16.05 billion of the $24.4 billion third-quarter revenue (Form 8-K, 29 October 2026).

Notes

  • Eli Lilly's results depend heavily on one molecule, tirzepatide, which is sold as Mounjaro for diabetes and Zepbound for obesity.
  • Eli Lilly regularly books acquired in-process research charges when it buys or licenses drugs, which can sharply change reported and non-GAAP EPS from one quarter to the next.
  • Lilly Endowment, a large long-term shareholder, periodically files Form 144 notices and sells blocks of Eli Lilly shares.

Sources